Search results
Added:
6 days ago
Source:
Arrhythmia Academy
A substudy of the ADVANTAGE AF trial has demonstrated that for treating typical atrial flutter (AFL), pulsed field ablation (PFA) is as effective and safe as conventional radiofrequency ablation (RFA), but significantly more efficient.¹ The study focused on adjunctive cavotricuspid isthmus (CTI) ablation, a common procedure performed during atrial fibrillation (AF) ablation.Mechanism of ActionPFA…
View more
Added:
3 weeks ago
ACC.26 - Dr Anuradha Lala-Trindade (Mount Sinai, New York, NY, US) provides her expert analysis of the most impactful late-breaking clinical trials presented at ACC.26, highlighting studies with the potential to influence clinical practice and shape future cardiovascular care. Key Late-Breaking Trials Discussed0:16 – STEMI-DTU: Primary Left Ventricular Unloading in Anterior ST-Segment Elevation…
View more
Added:
3 weeks ago
Source:
Interventional Cardiology Review Journal
For patients with atrial fibrillation (AF) at high risk for both stroke and bleeding, catheter-based left atrial appendage closure (LAAC) was not found to be non-inferior to physician-directed best medical care, according to the results of the CLOSURE-AF trial.¹MethodologyThe multicentre, randomised CLOSURE-AF trial was conducted in Germany to assess the effectiveness of LAAC compared with best…
View more
Thomas Pambrun
Author
Added:
1 year ago
TCT Conference 2024 - Join us for an engaging conversation with TCT Programme Director, Dr Sahil Parikh (Columbia University Irving Medical Center, US), as he delivers a concise and insightful overview of key late-breaking trials from the TCT 24 Conference. Dr Parikh discusses the pivotal studies that are set to reshape clinical practice and have a lasting impact on patient care.Trials covered in…
View more
Added:
1 hour ago
Source:
Radcliffe CKM
A post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse cardiovascular events (MACE) with…
View more
Added:
7 months ago
ESC Congress 2025 - New findings from STRIDE further demonstrate effectiveness of semaglutide in improving functional outcomes in PAD.Dr Subodh Verma joins us to discuss new findings from the STRIDE study, which investigated semaglutide 1.0mg in individuals with peripheral artery disease (PAD). 792 participants were enrolled in the trial, 24.6% of which were female, and 75.4% male.Findings showed…
View more
Added:
1 year ago
CRT 2024 — Prof Patrick W Serruys (National University of Ireland, Galway, US) joins us to discuss learning from the SYNTAX trial.The SYNTAX trial is a randomized controlled trial designed to evaluate the efficacy and safety of percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents versus coronary artery bypass grafting (CABG) in patients with complex coronary…
View more
Added:
7 months ago
ESC Congress 2025 – The fourth and final day of ESC Congress 2025 maintained momentum with transformative clinical data that will influence cardiovascular practice worldwide.Leading interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) offer their expert commentary on the standout hot line trials and their clinical significance from day four.Day 4…
View more